Impact of an Institution‐Specific Hospital‐Acquired Pneumonia Protocol on the Appropriateness of Antibiotic Therapy and Patient Outcomes

Study Objective. To evaluate the impact of a hospital‐acquired pneumonia (HAP) protocol on appropriateness of empiric antibiotic therapy, antibiotic deescalation, antibiotic duration, patient mortality, and length of stay.

[1]  J. Devlin,et al.  The Effect of ICU Sedation Guidelines and Pharmacist Interventions on Clinical Outcomes and Drug Cost , 1997, The Annals of pharmacotherapy.

[2]  Jordi Rello,et al.  Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. , 2002, Chest.

[3]  Larry J. Anderson,et al.  Guidelines for preventing health-care-associated pneumonia, 2003 recommendations of the CDC and the Healthcare Infection Control Practices Advisory Committee. , 2004, Respiratory care.

[4]  古谷 良輔,et al.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. , 2008, American journal of respiratory and critical care medicine.

[5]  M. Kollef.  Gram-negative bacterial resistance: evolving patterns and treatment paradigms. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  G Sherman,et al.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. , 1999, Chest.

[7]  S. Weingarten,et al.  Guidelines in pulmonary medicine: a 25-year profile. , 1999, Chest.

[8]  J. Gums,et al.  A Randomized, Prospective Study Measuring Outcomes after Antibiotic Therapy Intervention by a Multidisciplinary Consult Team , 1999, Pharmacotherapy.

[9]  J. Rello,et al.  De-escalation in lower respiratory tract infections , 2006, Current opinion in pulmonary medicine.

[10]  Marin H Kollef,et al.  Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. , 2005, Chest.

[11]  T. Karchmer,et al.  Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. , 2006, Chest.

[12]  J. Rello,et al.  Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: An observational, multicenter study comparing monotherapy with combination antibiotic therapy* , 2007, Critical care medicine.

[13]  C. Bridges,et al.  Guidelines for preventing health-care--associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. , 2004, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[14]  W. Knaus,et al.  APACHE II: a severity of disease classification system. , 1985 .

[15]  D. Craven,et al.  Epidemiology of nosocomial pneumonia. New perspectives on an old disease. , 1995, Chest.

[16]  Jessina C. McGregor,et al.  A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  D. Cardo,et al.  Estimating Health Care-Associated Infections and Deaths in U.S. Hospitals, 2002 , 2007, Public health reports.

[18]  Leonard Leibovici,et al.  β lactam monotherapy versus β lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials , 2004, BMJ : British Medical Journal.

[19]  A. Arroliga,et al.  Introduction of sedative, analgesic, and neuromuscular blocking agent guidelines in a medical intensive care unit: Physician and nurse adherence , 2000, Critical care medicine.

[20]  D A Rasley,et al.  Surveillance of nosocomial infections , 1989, Critical care nursing quarterly.

[21]  D. Cook,et al.  The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. , 1999, American journal of respiratory and critical care medicine.

[22]  Victoria J. Fraser,et al.  Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center* , 2003, Critical care medicine.

[23]  J. Burke,et al.  Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  Matthew Bidwell Goetz,et al.  Impact of clinical guidelines in the management of severe hospital-acquired pneumonia. , 2005, Chest.

[25]  L. Leibovici,et al.  Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. , 2004, BMJ.

[26]  M. Perreault,et al.  Impact of a Protocol for Prevention of Ventilator-Associated Pneumonia , 2007, The Annals of pharmacotherapy.

[27]  Mauricio Valencia,et al.  Ventilator-associated pneumonia , 2009, Current opinion in critical care.

[28]  Claude D Martin,et al.  Ventilator-associated pneumonia: Breaking the vicious circle of antibiotic overuse* , 2007, Critical care medicine.

[29]  M. Niederman,et al.  Resolution of ventilator-associated pneumonia: Prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome* , 2003, Critical care medicine.

[30]  Acip.  Prevention and control of influenza : recommendations of the Advisory Committee on Immunization Practices (ACIP) , 2004 .